Citigroup
SPRY icon

Citigroup’s ARS Pharmaceuticals SPRY Stock Holding History

Citigroup’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$714K Buy
89,199
+70,574
+379% +$607K ﹤0.01% 3690
2026
Q1 		$150K Buy
18,625
+61
+0.3% +$585 ﹤0.01% 4125
2025
Q4 		$216K Buy
18,564
+9,945
+115% +$96.7K ﹤0.01% 3972
2025
Q3 		$86.6K Sell
8,619
-28,964
-77% -$416K ﹤0.01% 4317
2025
Q2 		$656K Sell
37,583
-57,627
-61% -$832K ﹤0.01% 3455
2025
Q1 		$1.2M Sell
95,210
-5,473
-5% -$65.8K ﹤0.01% 3122
2024
Q4 		$1.06M Buy
100,683
+63,461
+170% +$889K ﹤0.01% 3318
2024
Q3 		$540K Buy
37,222
+10,803
+41% +$128K ﹤0.01% 3681
2024
Q2 		$225K Sell
26,419
-71,043
-73% -$630K ﹤0.01% 3824
2024
Q1 		$996K Buy
97,462
+92,223
+1,760% +$688K ﹤0.01% 3030
2023
Q4 		$28.7K Buy
5,239
+3,472
+196% +$15.2K ﹤0.01% 4831
2023
Q3 		$6.68K Sell
1,767
-18,205
-91% -$119K ﹤0.01% 4655
2023
Q2 		$134K Sell
19,972
-33,409
-63% -$223K ﹤0.01% 4098
2023
Q1 		$348K Sell
53,381
-41,633
-44% -$320K ﹤0.01% 3383
2022
Q4 		$810K Buy
95,014
+94,596
+22,631% +$614K ﹤0.01% 2811
2022
Q3 		$2K Sell
418
-322
-44% -$1.59K ﹤0.01% 5531
2022
Q2 		$3K Sell
740
-4,944
-87% -$17.2K ﹤0.01% 5799
2022
Q1 		$20K Sell
5,684
-1,571
-22% -$6.84K ﹤0.01% 5149
2021
Q4 		$48K Buy
7,255
+4,724
+187% +$38.4K ﹤0.01% 5086
2021
Q3 		$25K Buy
2,531
+1,542
+156% +$38K ﹤0.01% 5139
2021
Q2 		$31K Buy
989
+148
+18% +$4.75K ﹤0.01% 5067
2021
Q1 		$37K Sell
841
-14,243
-94% -$674K ﹤0.01% 4878
2020
Q4 		$699K Buy
+15,084
New +$504K ﹤0.01% 3908

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Citigroup's SPRY Position: Q2 2026 in Review

Citigroup increased its ARS Pharmaceuticals (SPRY) stake by 379% in Q2 2026, buying an estimated $607K and bringing the position to 89,199 shares worth $714K. The position accounts for ﹤0.01% of the portfolio, ranked #3690.

Citigroup first reported a position in SPRY in Q4 2020 and has held it in 23 quarters since. The position peaked at $1.2M in Q1 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Citigroup held 89,199 shares of ARS Pharmaceuticals worth $714K as of Q2 2026.
  • Citigroup bought 70,574 ARS Pharmaceuticals shares in Q2 2026, an estimated $607K.
  • ARS Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3690 holding.
  • Citigroup first reported a position in ARS Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • Citigroup's ARS Pharmaceuticals position peaked at $1.2M in Q1 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.